Here is a roundup of March 2025 U.S. FDA approvals across cancer subtypes, including prostate, bladder and gastrointestinal ...

The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 ...

TLX007-CDx was approved by the FDA for PSMA-PET scanning in adult male patients with prostate cancer with suspected ...

The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK said it has given a world-first approval to Rotop's ...

The Food and Drug Administration (FDA) has expanded the approval of Pluvicto® (lutetium Lu 177 vipivotide tetraxetan) to include patients with ...

Telix’s next-generation PSMA-PET imaging agent for prostate cancer, Gozellix receives US FDA approves: Melbourne, Australia Monday, March 24, 2025, 17:00 Hrs [IST] Telix, a biop ...

According to Telix Pharmaceuticals, the product has a longer shelf-life (up to 6 hours) and an extended distribution radius compared with other gallium-based products.

TLX007-CDx is a cold kit designed for the preparation of PSMA-targeted PET imaging for prostate cancer. It leverages ...

Telix’s Illuccix prostate cancer PSMA-PET imaging agent approved in the Netherlands: Melbourne, Australia Wednesday, March 19, 2025, 12:00 Hrs [IST] Telix, a biopharmaceutical c ...

Telix Pharmaceuticals Limited (ASX: TLX, Nasdaq: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) ...